Previous studies showed that CD36 gene expression was increased and correlated with liver fat content in patients with NAFLD [31], and CD36 deletion protected against the development of hepatic steatosis [32,33]; inhibiting the uptake of FFA into the hepatocyte can be affected by the inhibition of CD36 expression. Here, CD36 is linked to metabolic dysfunction-associated steatotic liver disease.